Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by FGPstockon Mar 08, 2023 7:55am
160 Views
Post# 35325320

RE:RE:It takes money to advance oncology R&D

RE:RE:It takes money to advance oncology R&D

 

this additional indication talk is just a bunch more smoke. They have discussed it for 7+ years and the reality is, no one is going to invest in additional indications until NMIBC is proved. If anyone . Per the Md&a's, Tlt is quoted 3-5 times that btd was to b Received in dec 2022. Also, the Covid research was supposed completed q4 2022. The Covid excuse doesn't work anymore. The fact that management  just alters their corporate presentation kick the timeline down the road w explanation is on them. They are still taking their salaries, bonuses, etc and they never perform to meet their own timelines. In regards to warren buffet, he is a great investor, but he would never even consider Tlt due to its record, management, bod, etc. he's smarter than ua

<< Previous
Bullboard Posts
Next >>